Publisher's Synopsis
This work on minimal residual disease in leukaemia covers immunotherapy in conjunction with autologous and allogenic bone marrow transplants, in-vitro manipulation of myeloid and lymphoid progenitors and the use of recombinant growth factors, long-term marrow culture and more.